Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Lyvgen Biopharma logo — Lyvgen is a bio-pharmaceutical company focused on developing...

Lyvgen Biopharma

Lyvgen is a bio-pharmaceutical company focused on developing novel agonist therapeutic antibodies for cancer.

Founded 2016 China Shanghai, China 19 employees Series C Total: $40.00M Biopharma, Health Care

General Information

Company Name Lyvgen Biopharma
Founded Year 2016
Location China Shanghai, China +2
Employees 19
Industries Biopharma, Health Care
Funding Stage Series C
Social

Get notified when Lyvgen Biopharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Lyvgen Biopharma

Lyvgen Biopharma, founded in 2016 and headquartered in China, is a biopharmaceutical company with a focus on developing novel therapies for cancer. The company's xLinkAb™ functional platform is dedicated to creating agonist antibodies (Abs) with tumor-localized immunostimulatory activities, achieving a balance with multiple functions of candidate Abs. With over 35 scientists with global pharmaceutical research and development experiences, Lyvgen's most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409 for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. The company has received a significant $10.00M Series C investment on 23 February 2021, with investors such as Chengwei Capital, IDG Capital, Longmen Capital, FTZ Fund. Lyvgen has initiated Phase I clinical trials of LVGN6051 in the USA, with plans to expand testing globally for LVGN7409 and LVGN1673, as well as Phase I trials in China for LVGN6051.

Taxonomy: bio-pharmaceutical, cancer therapy, agonist antibodies, biopharmaceutical research, immunostimulatory antibodies, oncology, Phase I clinical trial, monoclonal antibodies, bispecific antibodies, immune oncology, tumor microenvironment modulation, synthetic biology, cross-linking antibody platform, tumor immune agonistic antibody, immunotherapy

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		23 Feb 2021
Series B •••••• 2
Investor
•••• •••• 		18 Jul 2018

Lyvgen Biopharma Alternatives & Competitors

Lyvgen Biopharma vs
Arch Oncology
Arch Oncology United States

Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and develop...

Series C
7 employees
Biotechnology, Health and Wellness
Lyvgen Biopharma vs
Biosion
Biosion China

Delivering breakthrough therapeutics to patients globally

Series B
20 employees
Biopharma, Biotechnology
Lyvgen Biopharma vs
OSE Immunotherapeutics
OSE Immunotherapeutics France

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Grant
76 employees
Biotechnology, Medical Devices

FAQ About Lyvgen Biopharma

Lyvgen is a bio-pharmaceutical company focused on developing novel agonist therapeutic antibodies for cancer.
Lyvgen Biopharma was founded in 2016.
Lyvgen Biopharma is headquartered in Shanghai, China.
Lyvgen Biopharma operates in the following industries: Biopharma, Health Care.
Lyvgen Biopharma has approximately 19 employees.
Lyvgen Biopharma has completed 2 funding rounds, raising a total of $40.00M. The latest funding stage is Series C.
Top alternatives and competitors to Lyvgen Biopharma include Arch Oncology, Biosion, OSE Immunotherapeutics, Yumab GmbH, Abcuro, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lyvgen Biopharma and Arch Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lyvgen Biopharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes